Company Description
Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States.
The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing.
It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally.
The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists.
In addition, it provides non-surgical product technologies.
Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.
| Country | United States |
| IPO Date | Jun 18, 2021 |
| Industry | Medical - Instruments & Supplies |
| Sector | Healthcare |
| Employees | 32 |
| CEO | Kathy Lee-Sepsick M.B.A. |
Contact Details
Address: 3950 Johns Creek Court Suwanee, Georgia United States | |
| Website | https://www.femasys.com |
Stock Details
| Ticker Symbol | FEMY |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001339005 |
| CUSIP Number | 31447E105 |
| ISIN Number | US31447E1055 |
| Employer ID | 11-3713499 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Kathy Lee-Sepsick M.B.A. | Founder, President, Chief Executive Officer & Director |
| Daniel Scott Currie | Chief Operating Officer, Senior Vice President & Secretary |
| Dov Elefant | Chief Financial Officer |
| Christine Thomas | Senior Vice President of Regulatory & Clinical Affairs |
| Dr. James H. Liu M.D. | Chief Medical Officer |
| Dr. Jeffrey Marcus M.D., M.S. | Chief Medical Advisor |
| Mary An Merchant J.D., Ph.D. | Vice President of Counsel & Intellectual Property |
| Naomi Phaneuf | Vice President of Marketing |
| Richard Spector | Chief Commercial Officer |
| Sue Owens | Vice President of Sales |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 12, 2024 | 8-K/A | [Amend] Current Report |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Oct 29, 2024 | 8-K | Current Report |
| Sep 11, 2024 | 8-K | Current Report |
| Sep 09, 2024 | 8-K | Current Report |
| Aug 30, 2024 | 8-K | Current Report |
| Aug 29, 2024 | 8-K | Current Report |
| Aug 08, 2024 | 10-Q | Quarterly Report |
| Aug 08, 2024 | 8-K | Current Report |